What guidance did Pediatrix Medical's management provide for the next earnings period?

What were the key takeaways from Pediatrix Medical's earnings call?

What is the market's earnings forecast for Pediatrix Medical next quarter?

Did Pediatrix Medical beat or miss consensus estimates last quarter?

What factors drove the changes in Pediatrix Medical's revenue and profit?

What is Pediatrix Medical's gross profit margin?

What is Pediatrix Medical's latest dividend and current dividend yield?

What does Pediatrix Medical do and what are its main business segments?

- **Record EBITDA Growth**: $87 million Q3 adjusted EBITDA, up 12% year-over-year, with 1.7 million shares repurchased.
- **Technology Differentiation**: BabySteps system reduces NICU documentation by 30%, driving clinical efficiency and outcomes.
- **Financial Strength**: 1x net leverage and $340 million cash provide flexibility for growth.
- **Strategic Focus**: Neonatology leadership with 1,300+ physicians and 37 million patient-day data warehouse.


**【CEO Remarks】**
- **Strong Q3 Results**: Adjusted EBITDA of $87 million exceeded expectations, driven by portfolio restructuring and expense control. Full-year outlook for adjusted EBITDA is $270–$290 million, reflecting cautious optimism.
- **Share Buybacks**: 1.7 million shares repurchased year-to-date, signaling confidence in long-term value.
- **Strategic Focus**: Emphasized neonatology leadership with 1,300+ physicians and BabySteps technology, a proprietary system improving NICU outcomes through clinical decision support and reduced documentation burden.
- **Research and Innovation**: 1,395 peer-reviewed publications and 72 clinical studies, positioning as a leader in neonatal research and quality care.

**【CFO Financial Commentary】**
- **Revenue Performance**: Consolidated revenue decline due to restructuring, but same-unit growth of 8% (pricing +7.5%, volumes +0.4%). Key drivers: RCM collections, acuity, administrative fees, and favorable payer mix.
- **Cost Management**: Operating cash flow of $138 million (vs. $96 million prior year), ending with $340 million cash and net debt of $260 million (1x leverage ratio).
- **Non-Operating Income**: $21 million gain from divested businesses, offsetting modest G&A increases.

**【Q&A Highlights】**
- **Capital Allocation**: Cautious on debt but open to strategic acquisitions; share buybacks continue as a priority.
- **Pricing Durability**: Collections (33%), acuity (20%), and administrative fees (10%) drove Q3 pricing; expect variability in 2026.
- **Market Dynamics**: Strong demand for neonatal support from hospitals; BabySteps technology differentiates Pediatrix in competitive landscape.
- **Subsidy Impact**: Hopeful about exchange plan subsidies but no direct impact on business observed.


Pediatrix Medical Group, Inc. (MD) Q3 2025 Earnings Call Transcript

- **Q2 EBITDA Beat**: $73 million vs. prior guidance, driven by 6% same-unit revenue growth and strong RCM collections.
- **Guidance Update**: Full-year EBITDA raised to $245-255 million, reflecting second-half visibility.
- **Cash Strength**: $225 million cash on hand, with plans to reach $350-400 million by year-end.
- **Admin Fees Growth**: 1/3 of pricing growth in Q2, with 30-40% corporate benefit and immediate impact.
- **Resilience in Turbulence**: 60% of volume in non-expansion states; strategic focus on high-acuity services.

**【CEO Opening Remarks】**
- Q2 2025 adjusted EBITDA of $73 million exceeded expectations, driven by 6% same-unit revenue growth from higher NICU days (up 6%), acuity levels, and RCM collections.
- Full-year EBITDA guidance raised to $245-255 million (narrowed from $235-260 million), reflecting second-half visibility.
- Emphasized strong cash position ($225 million) and balance sheet resilience in a challenging healthcare environment.
- Highlighted strategic addition of Greg Neeb to bolster financial and operational initiatives.

**【CFO Financial Commentary】**
- Consolidated revenue decreased 7% due to non-same-unit activity ($63 million decline), offset by 6% same-unit growth.
- Same-unit pricing up 3.5% from higher acuity, RCM collections, and admin fees; volumes up 3% in neonatology and maternal fetal medicine.
- G&A expenses decreased 3% due to prior-year staffing reductions; D&A down 40% from practice dispositions.
- Operating cash flow of $138 million (vs. $109 million prior year) driven by earnings and deferred tax payments.
- Cash balance expected to reach $350-400 million by year-end, with net leverage at 1.5x.

**【Q&A Highlights】**
- **Admin Fees Contribution**: 1/3 of Q2 pricing growth (vs. 10% in Q1), with 30-40% flow-through to corporate and immediate impact.
- **NICU Growth Drivers**: Combination of acuity increases, strong partnerships, and no single market share shift.
- **Big Beautiful Bill Impact**: 60% of volume in non-expansion states; potential limited impact on high-acuity maternal/child services.
- **Buyback Strategy**: Flexible capital allocation with focus on debt reduction and selective share repurchases.
- **2025 Outlook**: Margins expected to remain stable, with tougher comps in H2 due to 2024 volume growth.

Pediatrix Medical Group, Inc. (MD) Q2 2025 Earnings Call Transcript

- **Q1 EBITDA Surpass**: $49M vs. prior $215M-$235M guidance, updated to $220M-$240M for 2025.
- **Revenue Growth Drivers**: 6% same-unit expansion from NICU volumes (+2%) and pricing (+4.6%).
- **Cost Efficiency**: Salary growth decelerated 4Qs in a row, offsetting higher incentive pay.
- **Strategic Wins**: New contracts with hospital systems highlight partner preference for Pediatrix's reliability.
- **Leverage Position**: 2.2x net debt/EBITDA with $99M cash, supporting opportunistic M&A.

**【CEO Opening Remarks】**
- Q1 2025 revenue exceeded expectations with same-unit growth of 6%, driven by 2% NICU days increase and favorable payer remits.
- Adjusted EBITDA of $49M surpasses guidance, leading to updated full-year outlook of $220M-$240M.
- Emphasis on cost management: salary expense deceleration for 4 consecutive quarters, partially offset by higher incentive compensation.
- Strategic focus on strengthening hospital partnerships and physician recruitment to drive growth.

**【CFO Financial Breakdown】**
- Total revenue down 7% YoY due to $63M decline from portfolio restructuring, offset by 6% same-unit growth.
- Same-unit pricing up 4.6% from payer mix improvements and RCM efficiency.
- Practice-level SW&B expenses increased YoY but salary growth decelerated sequentially.
- G&A expenses decreased 12% YoY from shared services staffing reductions.
- Cash flow used $116M Q1, ending with $99M cash and 2.2x net leverage.
- DSO improved to 48 days, down 4 days YoY from AR collections.

**【Q&A Key Takeaways】**
- **Guidance Adjustments**: Q1 outperformance justified EBITDA raise, but 2025 outlook remains cautious due to healthcare/economic uncertainty.
- **Hospital Subsidies**: Stable as part of normal business relationships, no material changes noted.
- **Acquisition Strategy**: Favorable environment for selective deals, especially in core neonatal/maternity services.
- **Collections Risk**: AR quality strong, no material risk of write-offs.
- **Seasonality**: No unusual patterns expected; Q1 EBITDA at ~20% of annual target aligns with historical trends.

Pediatrix Medical (MD)-6 May 25-2025 Q1 Earnings call transcript

- **2024 Performance Standout**: $69 million Q4 EBITDA beat, driven by 8.7% same-unit revenue growth and $30 million EBITDA benefit from exiting low-margin practices.
- **2025 Outlook Caution**: $215-$235 million EBITDA range reflects cautious approach amid wage inflation and uncertain payer mix, with 1.7x net leverage as a safety net.
- **Strategic Focus**: Hospital partnerships and clinician recruitment key to long-term growth, with RCM stabilization and wage trend deceleration as near-term priorities.

**【CEO Summary Section】**
- **Fourth Quarter and Full Year 2024 Performance**: Achieved strong same-unit revenue growth driven by favorable payer mix and volumes, with adjusted EBITDA of $69 million exceeding expectations. Completed portfolio restructuring, exiting $200 million in low-margin revenue, and transitioned to a hybrid RCM model.
- **2025 Strategic Priorities**: Focus on patient-centric care, strengthening hospital relationships, and prudent financial stewardship. Guided 2025 adjusted EBITDA of $215-$235 million, reflecting a midpoint increase of $225 million compared to 2024's $220 million (adjusted for leap year).
- **Balance Sheet Strength**: Net debt of 1.7x EBITDA provides flexibility in uncertain healthcare environment.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Consolidated revenue growth of 1% (8.7% same-unit), with SW&B expenses decelerating but still above historical 2-3% range. Operating cash flow of $135 million reduced net debt to $386 million, ending the year with $230 million in cash.
- **2025 Outlook Parameters**: Full-year revenue of $1.8 billion, G&A expense of $220-$230 million, and EBITDA guidance of $215-$235 million. Includes $30 million annual EBITDA benefit from portfolio restructuring (1/3 realized in 2024) and no M&A contribution.
- **Key Risks**: Payer mix tailwind may level off, wage inflation remains a headwind, and RCM performance stabilization is a focus.

**【Q&A Highlights】**
- **2025 Growth Drivers**: Flat volume assumptions, stable managed care, and RCM efficiency improvements. Payer mix impact on 2024 EBITDA was ~$10 million, but 2025 outlook assumes no comp benefit.
- **Hospital Relationships**: Systematic engagement to strengthen partnerships and explore fee support opportunities, though not baked into guidance.
- **Capital Allocation**: Prioritize balance sheet strength; no immediate M&A plans, but open to opportunities as sector evolves.
- **IVF Tailwind**: Potential long-term opportunity, but not yet quantified or incorporated into financials.

Pediatrix Medical (MD)-20 Feb 25-2024 Q4 Earnings call transcript

Pediatrix Medical (MD)-1 Nov 24-2024 Q3 Earnings call transcript

Pediatrix Medical (MD)-6 Aug 24-2024 Q2 Earnings call transcript

Pediatrix Medical Group, Inc. (MD) Q1 2024 Earnings Call Transcript

- **2024 EBITDA Guidance**: $200-220 million, reflecting RCM transition and G&A efficiency. 
- **Stable Pricing & Volumes**: 2024 outlook assumes flat year-over-year. 
- **90% Arbitration Win Rate**: Improved success in out-of-network claims. 
- **Leverage & Liquidity**: 2.8x net leverage, $73 million cash. 
- **Q1 EBITDA Range**: 17-19% of full year, wider guidance due to operational execution risks.

**【CEO Summary Section】**
- **2024 Outlook**: Adjusted EBITDA guidance of $200-220 million, driven by three priorities: RCM transition, G&A efficiency, and in-network payer relationships. 
- **RCM Transition**: Hybrid model with internal team expansion and new vendor engagement, no disruptions in Q4 2023. 
- **Payer Relationships**: 95%+ in-network status, successful arbitrations (90% win rate) for out-of-network claims. 
- **Practice Margin**: Plans to stabilize margins through structural, tactical, and strategic changes (e.g., staffing mix, contract renewals). 

**【CFO Financial Commentary】**
- **Q4 2023 Results**: Same-unit volumes mixed (strong maternal fetal medicine offset by lower hospital-based services). 
- **Pricing Distortions**: 2% reduction from prior RCM vendor support and 40bps from non-recurring care dollars. 
- **Cost Management**: Stable practice-level expenses (mid-single-digit salary growth), G&A as % of revenue comparable to 2023. 
- **Liquidity**: $73 million cash, $628 million borrowings, 2.8x net leverage. 
- **2024 Guidance**: Net revenue $2-2.1 billion, 17-19% of EBITDA in Q1. 

**【Q&A Key Highlights】**
- **RCM Transition Impact**: Stable pricing expected in 2024, no tailwind from prior RCM headwinds. 
- **Arbitration Success**: 90% win rate in CMS reopened portal. 
- **Free Cash Flow**: ~70% conversion of EBITDA to operating cash flow. 
- **Volume & Pricing**: Stable volumes and rates, with no meaningful movement. 
- **Capital Deployment**: Active in acquiring practices, focusing on core specialties. 



MD

MD fundamentals

Earnings Call

You can ask Aime